← Back to Search

Behavioural Intervention

Repetitive Transcranial Magnetic Stimulation (rTMS) for Autism Spectrum Disorder

N/A
Recruiting
Led By Krystal L Parker, Ph.D
Research Sponsored by Krystal Parker, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.
Awards & highlights

Study Summary

This trial will test whether electrical brain stimulation can help improve cognition and mood in patients with various mental disorders.

Who is the study for?
This trial is for individuals with schizophrenia, autism, bipolar disorder, Parkinson's disease, or major depression. Participants must be able to consent and not have a recent substance use disorder (except tobacco), uncontrolled high blood pressure, significant heart disease, kidney disease, seizures/epilepsy or certain other medical conditions.Check my eligibility
What is being tested?
The study tests if cerebellar stimulation using Repetitive Transcranial Magnetic Stimulation (rTMS) can improve cognitive function and mood in patients. Some will receive real rTMS while others get a sham treatment to compare outcomes.See study design
What are the potential side effects?
Possible side effects of rTMS include headache, scalp discomfort at the site of stimulation, tingling or spasms in facial muscles. Rarely it may cause seizures or hearing loss if ear protection isn't used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in disease-specific symptom rating scale, one scale identified for each group (MADRS for bipolar group; PANSS for schizophrenia group; UPDRS in Parkinson's patient group).
Secondary outcome measures
Bipolar group: Change in Columbia Suicide Severity Rating Scale.
Bipolar group: Change in Young Mania Rating Scale.
Change in CGI.
+12 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: patient active rTMSExperimental Treatment1 Intervention
Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
Group II: Control active rTMSActive Control1 Intervention
Group III: Control sham rTMSPlacebo Group1 Intervention
Group IV: patient sham rTMSPlacebo Group1 Intervention
Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation (rTMS)
2019
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

Krystal Parker, PhDLead Sponsor
Krystal L Parker, Ph.DPrincipal InvestigatorUniveristy of Iowa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the estimated size of this research endeavor?

"Affirmative, according to clinicaltrials.gov this investigation is looking for volunteers. It was initially posted on November 30th 2017 and has recently been updated as of April 14th 2022. 200 people are necessary to be recruited from 1 hospital facility."

Answered by AI

Are there any openings to join this research endeavor?

"Affirmative. Clinicaltrials.gov shows that this research is actively recruiting volunteers to participate in the trial, which was initially posted on November 30th 2017 and subsequently edited on April 14th 2022. Specifically, 200 patients are sought from a singular site."

Answered by AI

Are applicants aged 45 or older being admitted into this experiment?

"The study's qualifications dictate that prospective participants must be between 18 and 90 years old. Notably, 623 clinical trials are available for people below the age of consent while 2027 medical studies target those over 65."

Answered by AI

What type of individuals are eligible to take part in this experiment?

"This clinical trial is looking for 200 individuals between 18 and 90 years old who have been diagnosed with schizophrenia. Furthermore, they must adhere to the necessary criteria in order to be successfully enrolled."

Answered by AI

Who else is applying?

What state do they live in?
New York
Illinois
Pennsylvania
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
University of Iowa
~10 spots leftby Aug 2024